Get the Stockscreener App
0.8849
1.07%
0.0094
Clearside Biomedical Inc stock is traded at $0.8849, with a volume of 65,220.
It is up +1.07% in the last 24 hours and up +9.50% over the past month.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
See More
Previous Close:
$0.8755
Open:
$0.88
24h Volume:
65,220
Relative Volume:
0.29
Market Cap:
$62.80M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-1.6696
EPS:
-0.53
Net Cash Flow:
$-19.91M
1W Performance:
+8.94%
1M Performance:
+9.50%
6M Performance:
-9.70%
1Y Performance:
-26.87%
1-Day Range:
$0.8528
$0.8899
1-Week Range:
$0.80
$0.8998
52-Week Range:
$0.7001
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
Name
Clearside Biomedical Inc
Sector
Industry
Phone
678-270-3631
Address
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Compare CLSD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.8849 | 62.80M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-24 | Initiated | Chardan Capital Markets | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-21 | Resumed | Wedbush | Outperform |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| May-13-20 | Initiated | ROTH Capital | Buy |
| Aug-09-19 | Downgrade | Needham | Buy → Hold |
| Nov-05-18 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-05-18 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-05-18 | Downgrade | Stifel | Buy → Hold |
| Mar-06-18 | Reiterated | Needham | Buy |
| May-25-17 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-17 | Initiated | JP Morgan | Overweight |
| Nov-10-16 | Reiterated | Needham | Buy |
| Oct-24-16 | Reiterated | Stifel | Buy |
View All
Clearside Biomedical Inc Stock (CLSD) Latest News
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - GlobeNewswire
Clearside Biomedical Announces Multiple Presentations to be Feat - GuruFocus
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting | CLSD Stock News - GuruFocus
Clearside Biomedical Showcases Suprachoroidal Injection Platform for Retinal Diseases at CTS Meeting - Nasdaq
Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Northern Trust Corp Has $157,000 Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical Approves Share Increase at Annual Meeting - TipRanks
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know - MSN
Clearside Biomedical (CLSD) Gets a Buy from H.C. Wainwright - The Globe and Mail
Clearside Biomedical’s SWOT analysis: eye disease stock faces funding hurdles amid promising pipeline - Investing.com India
Clearside Biomedical target cut to $5 by H.C. Wainwright - Investing.com
HC Wainwright Lowers Clearside Biomedical (NASDAQ:CLSD) Price Target to $5.00 - Defense World
Clearside Biomedical (CLSD) Price Target Lowered by Analyst | CL - GuruFocus
H.C. Wainwright Adjusts Price Target for Clearside Biomedical (C - GuruFocus
Clearside Biomedical (CLSD) Price Target Lowered by Analyst | CLSD Stock News - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the St - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum | CLSD Stock News - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - GlobeNewswire
Clearside Biomedical Reveals Next-Gen Eye Therapy Platform at Exclusive Stifel Conference - Stock Titan
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.00 - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.com - Defense World
Needham & Company LLC Lowers Clearside Biomedical (NASDAQ:CLSD) Price Target to $3.00 - Defense World
JMP maintains $5 target on Clearside Biomedical stock By Investing.com - Investing.com Nigeria
Clearside Biomedical (CLSD) Reiterates Market Outperform Rating - GuruFocus
Clearside Biomedical Reports Q1 2025 Financial Progress - TipRanks
Clearside Biomedical (CLSD) Target Price Lowered by Needham | CL - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates - MSN
Stifel maintains Buy on Clearside Biomedical, target at $8 By Investing.com - Investing.com South Africa
Stifel maintains Buy on Clearside Biomedical, target at $8 - Investing.com Australia
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings: EPS Matches Es - GuruFocus
Clearside (CLSD) Reports Strong Q1 Revenue Boost | CLSD Stock Ne - GuruFocus
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings: EPS Matches Estimates at -$0.11, Revenue Surges to $2.3 Million, Exceeding Expectations - GuruFocus
Clearside Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside (CLSD) Reports Strong Q1 Revenue Boost | CLSD Stock News - GuruFocus
Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Clearside Biomedical (NASDAQ:CLSD) Cut to “Sell” at StockNews.com - Defense World
Investor Network: Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
Clearside Biomedical Inc Stock (CLSD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clearside Biomedical Inc Stock (CLSD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | Chief Medical Officer |
Nov 01 '24 |
Buy |
1.00 |
36,500 |
36,500 |
100,000 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):